Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C1-esterase inhibitor (C1-INH) is a serine protease inhibitor (serpin) that regulates the complement and contact system pathways. It inhibits activated C1r and C1s (classical pathway), MASP2 (lectin pathway), plasma kallikrein, factor XIIa (FXIIa), factor XIa (FXIa), plasmin, and tissue plasminogen activator. Deficiency or dysfunction leads to hereditary angioedema (HAE), characterized by uncontrolled bradykinin production and severe swelling. Purified human or recombinant C1-INH is used to treat/prevent HAE attacks. Polyanions such as glycosaminoglycans may act as cofactors during complex formation.
Irreversible inhibition of target serine proteases (C1r, C1s, MASP2, plasma kallikrein, FXIIa, FXIa, plasmin, tissue plasminogen activator) by binding to their active sites via the reactive center loop (RCL).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement Component 1 Esterase Inhibitor (C1-INH).